Tamsulosin and Tadalafil in Relieving Benign Prostatic Hyperplasia Related Symptoms- A Comparative Study
Benign Prostatic Hyperplasia Related Symptoms
Background: Benign prostatic hyperplasia (BPH) is the most common neoplastic condition afflicting men and constitutes a major factor impact- ing the health of the male. The present study compared tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms in patients. Subjects and Methods: The present study was conducted at NRI Medical College & Hospital, Chinakakani, Mangalagiri Mandal, Andhra Pradesh from April 2007 to March 2008 on 82 men of >45 years of age with LUTS secondary to benign prostatic hyperplasia (BPH) with an IPSS >8. All patients were divided into 2 weeks. In group I, Tadalafil 10 mg once daily with an intervening 4-week period of placebo (P4) wash out followed by Tamsulosin 0.4 mg once daily were administered for a period of 6 weeks and in group II, reverse of it was administered. IPSS scores, Uroflowmetry parameters and International Index of Erectile Function-5 scores were recorded in both groups. Results: Age group 45- 55 years had 12, 55-65 years had 28 and >65 years had 42 patients. The difference was significant (P< 0.05). Comorbidities such as diabetes mellitus was present in 4 in group I and 5 in group II, bronchial asthma 5 in group I and 3 in group II, Hypertension was present in 7 in group I and 9 in group II and both hypertension and diabetes mellitus was present in 10 in group I and 12 in group II. The difference was significant (P< 0.05). Mean IPSS total score, IPSS voiding score, IPSS storage score and IPSS QOL score at baseline, 2 weeks and 8 weeks in group I and group II was non- significant (P> 0.05). Conclusion: Authors found that both Tadalafil and Tamsulosin improved LUTS and benign prostrate hyperplasia symptoms.
Mcneal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990;17:477–86.
Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between lower urinary tract symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function. J Sex Med. 2009;6:2299–304.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol. 2011;185(5):1793–1803. Available from: https://dx.doi.org/10.1016/j.juro.2011.01.074.
Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA. BJU Int. 1998;109:84–91.
Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urol. 2006;68(4):804–809. Available from: https://dx.doi.org/10.1016/j.urology.2006.04.019.
Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104(1):63–68. Available from: https://dx.doi.org/10.1111/j.1464-410x.2008.08317.x.
McVary KT, McKenna KE. The relationship between erec- tile dysfunction and lower urinary tract symptoms: Epidemi- ological, clinical, and basic science evidence. Current Urol Rep. 2004;5(4):251–257. Available from: https://dx.doi.org/10.1007/s11934-004-0047-1.
McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized, Double-Blind Trial. J Urol. 2007;177(3):1071–1077. Available from: https://dx.doi.org/10.1016/j.juro.2006.10.055.
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. J Urol. 2008;180(4):1228–1234. Available from: https://dx.doi.org/10.1016/j.juro.2008.06.079.
Pattanaik S, Sandhu HS, Mavuduru RS, Singh SK, Mandal AK. Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study. Indian J Urol. 2019;35(1):25–25.
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2008;53(6):1236–1244. Available from: https://dx.doi.org/10.1016/j.eururo.2008.01.075.
Madani AH, Afsharimoghaddam A, Roushani A, Farzan A, Asadollahzade A, Shakiba M. Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication. Int Braz J Urol. 2012;38(1):33–39. Available from: https://dx.doi.org/10.1590/s1677-55382012000100005.
Copyright (c) 2020 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.